US OptionsDetailed Quotes
SYRE250117C45000
- 1.10
- 0.000.00%
15min DelayClose Jan 3 16:00 ET
0.00High0.00Low
1.10Open1.10Pre Close0 Volume1 Open Interest45.00Strike Price0.00Turnover291.72%IV89.32%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry1.10Extrinsic Value100Contract SizeAmericanOptions Type0.1918Delta0.0209Gamma22.14Leverage Ratio-0.1438Theta0.0012Rho4.25Eff Leverage0.0122Vega
Spyre Therapeutics Stock Discussion
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
Spyre Therapeutics (NASDAQ: SYRE) has priced its public offering of 7,275,000 common stock shares at $27.50 per share, expecting to raise $200.0 million in gross proceeds. The clinical-stage biotech company, focused on IBD treatments, has granted underwriters a 30-day option to purchase up to additional 1,091,250 shares. The offering, managed by Jefferies, Goldman Sachs, Evercor...
Capital Markets: $UP Fintech (TIGR.US)$ $Cipher Mining (CIFR.US)$ $CleanSpark (CLSK.US)$
Biotechnology: $Genfit (GNFT.US)$ $Spyre Therapeutics (SYRE.US)$ $Krystal Biotech (KRYS.US)$
Software: $Verb Technology (VERB.US)$ $SurgePays (SURG.US)$ $Uber Technologies (UBER.US)$
Asset Management: $Westwood Holdings (WHG.US)$ $BrightSphere Investment (BSIG.US)$ $Blackrock (BLK.US)$
Specialty Industrial Machinery: $JE Cleantech Holdings Limited (JCSE.US)$ $Taylor Devices (TAYD.US)$ $CSW Industrials (CSWI.US)$
...
U.S. stocks advanced on Monday, building off a record finish ahead of the ramping up of fourth-quarter earnings season.
The $Dow Jones Industrial Average (.DJI.US)$ rose 138 points, or 0.26%, to 38,000. The $S&P 500 Index (.SPX.US)$ was up 10 points, or 0.22%, at 4,850. The $Nasdaq Composite Index (.IXIC.US)$advanced 49 points, or 0.32%, to 15,360.
While the S&P 500 finally returned to record territory on Friday, skeptic...
Spyre felt the positive pressure from fresh buy ratings by analysts like Stifel. $Ginkgo Bioworks (DNA.US)$ also roase 9%, despite a new sell rating from Goldman Sachs.
But monday morning was not al...
No comment yet